Michael E. Thase, MD

Caplyta boosts antidepressants in MDD, showing 2–4 week response with minimal weight, metabolic, and EPS risks.

The original STAR*D authors refute claims of a violated protocol.

What are the latest treatments in difficult to treat depression?

Michael E. Thase, MD; Theresa Cerulli, MD; Gustavo Alva, MD, DFAPA; and Tina Matthews-Hayes, DNP, FNP, PMHNP, provide insight on the role of telemedicine in improving outcomes for patients with bipolar disorder.

A panel of experts in psychiatry consider the use of a novel second-generation antipsychotic for the management of treatment resistant depression.

Michael E. Thase, MD, presents the case of a 47-year-old man with treatment resistant bipolar depression.

Psychiatric experts consider mood stabilizers when treating bipolar disorder and review the role of antidepressants in disease management.

Theresa Cerulli, MD, and Tina Matthew-Hayes, DNP, FNP, PMHNP, review diagnostic difficulties of the patient’s primary care physician in patient case #1 and share optimal approaches to the diagnosis and treatment for patients with bipolar disorder.

Tina Matthews-Hayes, DNP, FNP, PMHNP, comments on screening tools for bipolar disorder and Gustavo Alva, MD, DFAPA, shares his impressions from patient case #1.

A panel of experts in psychiatry share insights on the challenges and importance of making an accurate diagnosis of bipolar disorder.

Experts in psychiatry review the case of a 27-year-old woman who presents for evaluation of a complex depressive disorder.

Grief vs depression? MDD vs depressive episodes? SGAs in treatment-resistant depression? Treatment-emergent sexual dysfunction? Insights in this Q&A.

Identification of atypical features is important in the treatment of depression for both treatment selection and prognosis, especially when initial measures prove ineffective. The concept of atypical depression has evolved over many years, and now it appears timely for a further revision.

There are many rapidly effective treatments for mania in bipolar disorder. However, there are relatively few options for bipolar depression, and none that are rapidly effective-even though bipolar depression constitutes between 20% to 50% of all depressive disorders.

Dr Michael Thase touches on an APA presentation about newer applications of cognitive therapy for disorders such as schizophrenia and bipolar disorder.

There is evidence that the combination of medication and psychotherapy improves outcomes for many psychiatric illnesses. Among the several forms of psychotherapy that might be considered, cognitive-behavioral therapy (CBT) is the most extensively studied.

CBT is a comprehensive system of therapy that builds on core therapeutic values by using a wide range of reliable methods to produce cognitive and behavioral change.

Our perceptions about antidepressant efficacy have been inflated by the "file drawer" effect: the selective publication of positive studies and suppression of negative ones.